Albany Molecular Research Inc. (AMRI) Stock Price Up 1.7%
Albany Molecular Research Inc. (NASDAQ:AMRI) rose 1.7% during mid-day trading on Friday . The company traded as high as $14.55 and last traded at $14.52, with a volume of 110,873 shares changing hands. The stock had previously closed at $14.28.
Separately, Morgan Stanley reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Albany Molecular Research in a research note on Friday, August 5th.
The firm’s market capitalization is $504.12 million. The stock’s 50 day moving average price is $14.58 and its 200 day moving average price is $14.63.
Albany Molecular Research (NASDAQ:AMRI) last posted its quarterly earnings data on Thursday, August 4th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.04. The business earned $116.50 million during the quarter, compared to analysts’ expectations of $123.10 million. Equities analysts forecast that Albany Molecular Research Inc. will post $1.09 earnings per share for the current fiscal year.
In other Albany Molecular Research news, Director Kevin Oconnor sold 5,000 shares of Albany Molecular Research stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $14.41, for a total transaction of $72,050.00. Following the transaction, the director now owns 52,955 shares of the company’s stock, valued at $763,081.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.